JPMorgan Chase & Co. Has $646,000 Stake in Atyr PHARMA INC (NASDAQ:ATYR)

JPMorgan Chase & Co. lifted its holdings in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) by 467.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 178,532 shares of the company's stock after buying an additional 147,092 shares during the period. JPMorgan Chase & Co. owned approximately 0.21% of Atyr PHARMA worth $646,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the company. American Century Companies Inc. acquired a new stake in shares of Atyr PHARMA in the fourth quarter valued at $319,000. Kingswood Wealth Advisors LLC purchased a new stake in Atyr PHARMA in the 4th quarter valued at approximately $170,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Atyr PHARMA during the 4th quarter worth $144,000. D.A. Davidson & CO. acquired a new stake in shares of Atyr PHARMA in the 4th quarter worth approximately $141,000. Finally, Farther Finance Advisors LLC purchased a new stake in shares of Atyr PHARMA in the 4th quarter worth about $88,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

Atyr PHARMA Stock Performance

ATYR stock traded up $0.26 during trading on Friday, reaching $3.60. The company had a trading volume of 1,375,066 shares, compared to its average volume of 905,107. Atyr PHARMA INC has a twelve month low of $1.42 and a twelve month high of $4.66. The company has a market cap of $319.89 million, a price-to-earnings ratio of -3.83 and a beta of 0.95. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. The firm has a 50-day simple moving average of $3.29 and a 200-day simple moving average of $3.39.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. As a group, sell-side analysts expect that Atyr PHARMA INC will post -0.91 earnings per share for the current year.

Analyst Ratings Changes

ATYR has been the subject of several recent research reports. Leerink Partnrs raised Atyr PHARMA to a "strong-buy" rating in a research report on Tuesday, February 18th. Cantor Fitzgerald initiated coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They set an "overweight" rating on the stock. Leerink Partners began coverage on Atyr PHARMA in a report on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 target price on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research report on Friday, March 14th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $18.60.

Atyr PHARMA Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.